Kenneth H. Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kenneth H. Kim has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Andrew Li
Cedars-Sinai Medical Center
3 shared publicationsBj Rimel
3 shared publicationsKristin Taylor
Cedars-Sinai Medical Center, Los Angeles, CA, United States
3 shared publicationsAnthony Do
Cedars-Sinai Medical Center
2 shared publications- Christopher Mayer
Cedars-Sinai Medical Center, Los Angeles, CA, United States
2 shared publications - Dandi S. Huang
Cedars-Sinai Medical Center
2 shared publications
Latest Publications
- 22 December 2025
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 69 (1) , 1
Foreword: Artificial Intelligence in Gynecology: The Current and Future Landscape of AI in OB-GYN
- 22 December 2025
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 69 (1) , 1
Foreword: Artificial Intelligence in Gynecology: The Current and Future Landscape of AI in OB-GYN
- 11 March 2025
- Published by Springer Nature
- p. 245-254
Complications of Minimally Invasive Surgery
- Open Access
- 16 May 2024
- Published by F1000 Research Ltd in MedEdPublish
- Vol. 14, 34
Factors that influence the formation and impact of mentorship relationships for OB/GYN residents
Background Mentorship is critical for successful careers in academic medicine. There is a gap in the literature regarding specific qualities that make effective mentorship relationships for Obstetrics and Gynecology (OB/GYN) residents. This study aimed to identify the attributes most valued by OB/GYN residents in their mentorship relationships and to explore the factors influencing their choice of mentors. Methods We conducted a cross-sectional survey among OB/GYN residents, distributed electronically November 2021-March 2022. Demographic data, mentor qualities, satisfaction with current mentorship and mentee factors were identified. The survey incorporated questions adapted from the validated Ideal Mentor Scale assessing three mentor attributes: Integrity, Guidance, and Relationship. Data analysis involved descriptive statistics, Student’s t-tests, chi-squared tests, and Fisher’s Exact tests where appropriate. Results 48 of 60 (80%) of surveyed residents responded. Among the respondents, 72.9% were female and 29.1% identified as non-white. Integrity emerged as the most valued Ideal Mentor attribute. No statistically significant gender-based differences were observed in the preferences for mentor characteristics including gender of a mentor. Non-white respondents placed greater importance on having a mentor of the same race (p<0.01). Residents interested in subspecialties expressed a stronger preference for mentors with fellowship training (p<0.01) and shared research experiences (p=0.03). Conclusions OB/GYN residents seek mentors characterized by integrity and who are active in research and professional societies aligned with their interests. The data highlight the importance of considering race and subspecialty preferences in fostering influential and equitable mentorship for all residents.
- 16 May 2024
- Published by F1000 Research Ltd in MedEdPublish
- Vol. 14, 34
Open AccessFactors that influence the formation and impact of mentorship relationships for OB/GYN residents
Background Mentorship is critical for successful careers in academic medicine. There is a gap in the literature regarding specific qualities that make effective mentorship relationships for Obstetrics and Gynecology (OB/GYN) residents. This study aimed to identify the attributes most valued by OB/GYN residents in their mentorship relationships and to explore the factors influencing their choice of mentors. Methods We conducted a cross-sectional survey among OB/GYN residents, distributed electronically November 2021-March 2022. Demographic data, mentor qualities, satisfaction with current mentorship and mentee factors were identified. The survey incorporated questions adapted from the validated Ideal Mentor Scale assessing three mentor attributes: Integrity, Guidance, and Relationship. Data analysis involved descriptive statistics, Student’s t-tests, chi-squared tests, and Fisher’s Exact tests where appropriate. Results 48 of 60 (80%) of surveyed residents responded. Among the respondents, 72.9% were female and 29.1% identified as non-white. Integrity emerged as the most valued Ideal Mentor attribute. No statistically significant gender-based differences were observed in the preferences for mentor characteristics including gender of a mentor. Non-white respondents placed greater importance on having a mentor of the same race (p<0.01). Residents interested in subspecialties expressed a stronger preference for mentors with fellowship training (p<0.01) and shared research experiences (p=0.03). Conclusions OB/GYN residents seek mentors characterized by integrity and who are active in research and professional societies aligned with their interests. The data highlight the importance of considering race and subspecialty preferences in fostering influential and equitable mentorship for all residents.
- 1 October 2023
- Published by SAGE Publications in Journal of Gynecologic Surgery
- Vol. 39 (5) , 204-212
Robotics in Gynecologic Oncology: Past, Present, and Future
In the 20 years since its inception, robotic surgery has evolved greatly in its design and clinical use. Most recently, the approach to training and gaining proficiency in robotic surgery techniques has also matured. This article reviews the development of robotic surgery systems, the trajectory of their use for patients with benign and malignant gynecologic conditions, and the advances in novel technologies that are driving the applications of robotic surgery forward. (J GYNECOL SURG 39:204)
- 1 October 2023
- Published by SAGE Publications in Journal of Gynecologic Surgery
- Vol. 39 (5) , 204-212
Robotics in Gynecologic Oncology: Past, Present, and Future
In the 20 years since its inception, robotic surgery has evolved greatly in its design and clinical use. Most recently, the approach to training and gaining proficiency in robotic surgery techniques has also matured. This article reviews the development of robotic surgery systems, the trajectory of their use for patients with benign and malignant gynecologic conditions, and the advances in novel technologies that are driving the applications of robotic surgery forward. (J GYNECOL SURG 39:204)
- Open Access
- 15 September 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, S14
26 Patterns of palliative care referral and inpatient to outpatient palliative care transition in gynecological cancer patients with a focus on primary language: a single institution retrospective study
- 15 September 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, S14
Open Access26 Patterns of palliative care referral and inpatient to outpatient palliative care transition in gynecological cancer patients with a focus on primary language: a single institution retrospective study
- Open Access
- 15 September 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, S14
25 Crowdfunding pages identify unmet needs among gynecologic cancer patients
- 15 September 2023
- Published by Elsevier in Gynecologic Oncology Reports
- Vol. 48, S14
Open Access25 Crowdfunding pages identify unmet needs among gynecologic cancer patients
- Open Access
- 1 January 2023
- Published by KEAI Publishing in Intelligent Surgery
- Vol. 6, 21-24
Outcomes of single port robotic sacrocolpopexy compared with multi-port approaches
- 1 January 2023
- Published by KEAI Publishing in Intelligent Surgery
- Vol. 6, 21-24
Open AccessOutcomes of single port robotic sacrocolpopexy compared with multi-port approaches
- 9 September 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 166, S249
A descriptive analysis of posttreatment retention of patients with vulvovaginal dysplasia and malignancies (505)
- 9 September 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 166, S249
A descriptive analysis of posttreatment retention of patients with vulvovaginal dysplasia and malignancies (505)
- 1 June 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (16_suppl) , e17526
Endocervical adenocarcinoma biomarkers for immunotherapy: Descriptive analysis.
E17526 Background: Adenocarcinoma and adenosquamous carcinoma of the cervix are subtypes of HPV related cervical cancer. As virally mediated tumors, they have become an obvious choice for immunotherapy treatment approach. Currently, there is little information about the presence of immunological tumor markers among patients with endocervical adenocarcinomas. We hypothesized cervical adenocarcinomas highly express immunotherapy markers. Here we characterize the protein status of immunotherapy markers in a large single institution dataset. Methods: An IRB approved retrospective review of cervical adenocarcinoma and adenosquamous carcinoma was performed. We gathered original slides for each patient and performed immunohistochemistry (IHC) for tumor markers CD8, PDL1, TIM3 and LAG3. Demographic and pathologic data was captured. Patients were categorized by positivity percentage for each marker. Descriptive statistics and univariate analysis were used. Results: A total of 97 patients met criteria for the study and slides were available for staining in 68 patients. Demographic data showed a median age of 42 years old with majority of patients identifying as White at 66%, followed by Hispanic (13%), Asian (10%), other (7%) and Black (1%). Of the entire cohort, 75% were adenocarcinoma, 25% were adenosquamous carcinoma. Among those with recorded status, 82% were HPV positive, 14% had metastasis, and 13% had recurrence. On univariate analysis, adenocarcinoma was significantly more common in patients who were LAG3 < 1% or PDL < 1% (p = 0.002, p = 0.007). Patients who were LAG3 < 1% or PDL < 1% were also less likely to have Grade 1 tumors (p = 0.006, 0.03). When analyzing by respective immune marker percentage group there were no statistically significant differences in LVSI, depth of invasion, stage, or recurrence rate. By IHC, 68% were PDL1 > 1% positive, 63% were LAG3 > 1% positive, 100% were TIM3 > 1% positive, 100% were CD8 > 1% positive. Seven of the 68 patients had a recurrence. Of those patients with recurrence, one was treated with immunotherapy. Conclusions: A large proportion of cervical adenocarcinomas displayed immunotherapy targets by IHC suggesting that combined immunotherapy agents may be useful in this population. Further study is needed to assess whether IHC is predictive of outcome or response.
- 1 June 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (16_suppl) , e17526
Endocervical adenocarcinoma biomarkers for immunotherapy: Descriptive analysis.
E17526 Background: Adenocarcinoma and adenosquamous carcinoma of the cervix are subtypes of HPV related cervical cancer. As virally mediated tumors, they have become an obvious choice for immunotherapy treatment approach. Currently, there is little information about the presence of immunological tumor markers among patients with endocervical adenocarcinomas. We hypothesized cervical adenocarcinomas highly express immunotherapy markers. Here we characterize the protein status of immunotherapy markers in a large single institution dataset. Methods: An IRB approved retrospective review of cervical adenocarcinoma and adenosquamous carcinoma was performed. We gathered original slides for each patient and performed immunohistochemistry (IHC) for tumor markers CD8, PDL1, TIM3 and LAG3. Demographic and pathologic data was captured. Patients were categorized by positivity percentage for each marker. Descriptive statistics and univariate analysis were used. Results: A total of 97 patients met criteria for the study and slides were available for staining in 68 patients. Demographic data showed a median age of 42 years old with majority of patients identifying as White at 66%, followed by Hispanic (13%), Asian (10%), other (7%) and Black (1%). Of the entire cohort, 75% were adenocarcinoma, 25% were adenosquamous carcinoma. Among those with recorded status, 82% were HPV positive, 14% had metastasis, and 13% had recurrence. On univariate analysis, adenocarcinoma was significantly more common in patients who were LAG3 < 1% or PDL < 1% (p = 0.002, p = 0.007). Patients who were LAG3 < 1% or PDL < 1% were also less likely to have Grade 1 tumors (p = 0.006, 0.03). When analyzing by respective immune marker percentage group there were no statistically significant differences in LVSI, depth of invasion, stage, or recurrence rate. By IHC, 68% were PDL1 > 1% positive, 63% were LAG3 > 1% positive, 100% were TIM3 > 1% positive, 100% were CD8 > 1% positive. Seven of the 68 patients had a recurrence. Of those patients with recurrence, one was treated with immunotherapy. Conclusions: A large proportion of cervical adenocarcinomas displayed immunotherapy targets by IHC suggesting that combined immunotherapy agents may be useful in this population. Further study is needed to assess whether IHC is predictive of outcome or response.
- 1 January 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 164 (1) , 1-2
MLH-1 methylation in endometrial cancer correlates to poor outcome, race, and comorbidities
- 1 January 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 164 (1) , 1-2
MLH-1 methylation in endometrial cancer correlates to poor outcome, race, and comorbidities